You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The company has shipped more than 12 million ID Now tests across the US and more than 30 million total COVID-19 tests since March.
BioFire's test is designed to detect and differentiate between SARS-CoV-2 and other respiratory pathogens, while UMass Medical's test is only for SARS-CoV-2.
The single-use, multiplex immunoassay provides results in 15 minutes and detects antibodies to HIV types 1 and 2 as well as Treponema pallidum.
Tempus' test is a modified version of Thermo Fisher Scientific's Applied Biosystems TaqPath COVID-19 Combo Kit, which previously received EUA from the FDA.
The tests are designed to detect viral nucleic acid in various respiratory specimens including nasal swabs, nasal aspirate, and bronchoalveolar lavage.
Of the 32 companies in the index, 21 firms saw their stock prices increase, while 11 firms' share prices decreased.
The three antibody tests may be used by any laboratory CLIA-certified to perform moderate- or high-complexity tests, the FDA authorizations said.
The single-visit blood test is one of two FDA-cleared alternatives to the traditional tuberculin skin test, according to Oxford Immunotec.
BillionToOne's assay detects SARS-CoV-2 in samples from nasal, nasopharyngeal, and oropharyngeal swabs and has a testing capacity of 1 million tests per day.
The test, which is also CE marked, is designed to run on the company's MosaiQ platform for blood grouping and transfusion-transmitted infection screening.